This psychedelic therapy FAQ compiles the most common and most important questions from people seriously considering psilocybin or other psychedelic-assisted approaches. The answers here are grounded in current clinical research, verified legal data, and practical...
The two most widely followed microdosing protocols are the Fadiman protocol (one day on, two days off) and the Stamets Stack (four or five days on, two or three days off, with lion’s mane and niacin added). Both emerged from citizen science rather than clinical...
Somatic integration after a psychedelic experience refers to the process of using body-based practices to help your nervous system process, stabilize, and anchor what surfaced during the experience. Insights from a psychedelic journey do not always translate into...
Research into psilocybin aging effects is accelerating, with preclinical studies pointing to neuroplasticity promotion, reduced neuroinflammation, and improvements in longevity biomarkers. The findings are genuinely interesting, but human data remains limited, and...
Research into psilocybin for end-of-life anxiety has produced some of the most compelling clinical data in psychedelic science. Landmark trials at Johns Hopkins and NYU found that a single guided psilocybin session produced significant, lasting reductions in anxiety,...
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal executive order directing agencies to accelerate review. The evidence shows real potential for...
